Bone-Derived Hormone Suppresses Appetite in Mice
Scientists discover new mechanism that regulates food intake and blood sugar
NEW YORK, NY (March 8, 2017)—A hormone secreted by bone cells can suppress appetite, according to mouse studies conducted by Columbia University Irving Medical Center (CUIMC) researchers. The hormone—called lipocalin 2—turns on neurons in the brain that have been previously linked to appetite suppression. The findings reveal a previously unknown mechanism for regulating the body’s energy balance and could lead to new targeted therapies for the treatment of obesity, type 2 diabetes, and other metabolic disorders.
The study was published online today in the journal Nature.
“In recent years, studies at CUIMC and elsewhere have shown that bone is an endocrine organ and produces hormones that affect brain development, glucose balance, kidney function, and male fertility,” says study leader Stavroula Kousteni, PhD, associate professor of physiology & cellular biophysics (in medicine) at Columbia. “Our findings add a critical new function of bone hormones to this list—appetite suppression—which may open a wholly new approach to the treatment of metabolic disorders.”
In 2007, a Columbia team led by Gerard Karsenty, MD, PhD, the Paul A. Marks Professor of Genetics & Development, professor of medicine, and chair, Department of Genetics & Development at CUIMC, was the first to discover that bone is an endocrine organ that regulates energy metabolism through the release of a hormone called osteocalcin. “We hypothesized that there were additional bone hormones that regulate metabolism, since other endocrine organs that affect metabolism usually do so through multiple hormones,” said Dr. Kousteni.
The first clues to a second hormone came in 2010, when Dr. Kousteni discovered that disabling a gene called FOXO1 in mouse osteoblasts (bone-forming cells) caused the mice to eat less and improved their glucose balance. “Since osteocalcin does not regulate appetite, we knew that a second bone hormone had to be involved in this process,” said Dr. Kousteni.
In the current study, the CUIMC researchers demonstrated that FOXO1-deficient osteoblasts express unusually high amounts of a protein called lipocalin 2. Lipocalin 2 was thought to be primarily secreted by adipocytes (fat cells) and to contribute to obesity. But the researchers showed that lipocalin 2 levels are 10 times higher in osteoblasts than in adipocytes. The researchers then engineered mice that lack lipocalin 2 in their osteoblasts or in fat cells. Only mice without the hormone in their osteoblasts showed increased appetite and compromised metabolism.
Lipocalin 2 also affected appetite and weight gain in normal-weight mice and in mice that were obese due to a lack of the leptin receptor and leptin signalling. In both types of mice, lipocalin 2 suppressed appetite, improved overall metabolism, and reduced body weight.
Dr. Kousteni and her team also found that lipocalin 2 crosses the blood-brain barrier. In the brain, the protein binds to and activates melanocortin 4 receptor (MC4R) neurons in the hypothalamus, the primary brain region that regulates appetite. MC4R neurons are known to be involved in triggering appetite suppression.
“The hope is that lipocalin 2 might have the same effects in humans, and that our findings can be translated into the development of therapies for obesity and other metabolic disorders,” said Dr. Kousteni.
Initial findings in humans are encouraging. In an analysis of patients with type 2 diabetes, the researchers found that blood levels of lipocalin 2 were inversely correlated with body weight and blood A1c levels, a long-term measure of blood sugar. “In other words, patients with higher lipocalin 2 levels had lower body weight and better glucose balance,” said Dr. Kousteni.
The study is titled “MC4R-dependent suppression of appetite by bone-derived lipocalin 2.” The other contributors are Ioanna Mosialou (CUIMC), Steven Shikhel (CUIMC), Jian-Min Liu (CUIMC), Antonio Maurizi (CUIMC), Na Luo (CUIMC), Zhenyan He (Southern Medical University, Guangzhou, China, and University of Texas Southwestern Medical Center at Dallas, Dallas, TX), Yiru Huang (Southern Medical University and University of Texas Southwestern Medical Center), Haihong Zong (Albert Einstein College of Medicine, Bronx, NY), Richard A. Friedman (CUIMC), Jonathan Barasch (CUIMC), Patricia Lanzano (CUIMC), Liyong Deng (CUIMC), Rudolph L. Leibel (CUIMC), Mishaela Rubin (CUIMC), Thomas Nicholas (CUIMC), Wendy Chung (CUIMC), Lori M. Zeltser (CUIMC), Kevin W. Williams (University of Texas Southwestern Medical Center), and Jeffrey E. Pessin (Albert Einstein College of Medicine).
The study was funded by grants from the National Institutes of Health (R01AR054447, P01AG032959, R01AR055931, R01DK100699, R01DK52431, P30DK26687, and P30DK063608), NOVO Nordisk, an NIH T32 Training Grant DK07328.
The researchers declare no competing financial conflicts of interest.
Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. Columbia University Irving Medical Center shares a campus with its hospital partner, NewYork-Presbyterian. For more information, visit cuimc.columbia.edu or columbiadoctors.org.